ImmunoGen Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

ImmunoGen şirketinin kazançları yıllık ortalama -5% oranında azalırken, Biotechs sektörünün kazançları yıllık 7.7% oranında artan oldu. Gelirler yıllık ortalama 23.3% oranında artan oldu.

Anahtar bilgiler

-5.0%

Kazanç büyüme oranı

12.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi	-14.6%
Gelir büyüme oranı	23.3%
Özkaynak getirisi	-13.1%
Net Marj	-25.6%
Son Kazanç Güncellemesi	30 Sep 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

ImmunoGen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:IMU Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 23	288	-74	156
30 Jun 23	190	-180	152
31 Mar 23	121	-240	139
31 Dec 22	109	-223	116
30 Sep 22	96	-201	88
30 Jun 22	89	-161	64
31 Mar 22	92	-129	50
31 Dec 21	70	-139	44
30 Sep 21	128	-71	40
30 Jun 21	137	-56	40
31 Mar 21	135	-49	40
31 Dec 20	132	-44	39
30 Sep 20	91	-71	39
30 Jun 20	86	-70	38
31 Mar 20	87	-89	37
31 Dec 19	82	-104	38
30 Sep 19	51	-151	38
30 Jun 19	48	-176	38
31 Mar 19	42	-174	38
31 Dec 18	53	-169	37
30 Sep 18	79	-140	36
30 Jun 18	77	-150	36
31 Mar 18	107	-117	36
31 Dec 17	115	-96	34
30 Sep 17	90	-117	33
30 Jun 17	89	-105	35
31 Mar 17	57	-142	35
31 Dec 16	49	-157	39
30 Sep 16	53	-156	38
30 Jun 16	60	-145	34
31 Mar 16	65	-129	35
31 Dec 15	57	-119	31
30 Sep 15	87	-72	29
30 Jun 15	86	-61	28
31 Mar 15	79	-57	27
31 Dec 14	74	-73	26
30 Sep 14	56	-82	25
30 Jun 14	60	-71	24
31 Mar 14	58	-67	23
31 Dec 13	76	-31	22
30 Sep 13	49	-59	22
30 Jun 13	36	-73	21
31 Mar 13	35	-73	27

Kaliteli Kazançlar: IMU şu anda kârlı değil.

Büyüyen Kar Marjı: IMU şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: IMU kârlı değildir ve zararlar son 5 yılda yılda 5% oranında artmıştır.

Büyüme Hızlandırma: IMU 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: IMU kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -18.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: IMU hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -13.09% ) sahiptir.

ImmunoGen Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2023 earnings released: EPS: US$0.11 (vs US$0.31 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.24 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.095 loss in 1Q 2022)

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Forecast breakeven date pushed back to 2024

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Insider recently sold €1.4m worth of stock

Forecast breakeven date moved forward to 2023

Third quarter 2023 earnings released: EPS: US$0.11 (vs US$0.31 loss in 3Q 2022)

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

New major risk - Share price stability

Insider recently sold €1.2m worth of stock

ImmunoGen, Inc. Announces Executive Changes

President recently sold €15m worth of stock

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

Forecast breakeven date moved forward to 2024

ImmunoGen, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.24 loss in 2Q 2022)

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.095 loss in 1Q 2022)

No longer forecast to breakeven

Forecast to breakeven in 2025

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunoGen, Inc. Appoint Executives

Forecast to breakeven in 2024

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

Forecast to breakeven in 2024

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

ImmunoGen, Inc. Announces Mature Data from Forward II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin in Recurrent Ovarian Cancer, Regardless of Platinum Status

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.17 loss in 1Q 2020)

ImmunoGen, Inc. Provides Revenue Guidance for the Year of 2021

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin